| Literature DB >> 32359482 |
Ellen Heitzer1, Lisa Auinger2, Michael R Speicher3.
Abstract
Cell-free DNA (cfDNA) is evolving into a widely used prognostic and predictive biomarker, particularly in oncology. However, its versatile clinical use precedes a profound understanding of the underlying biology of cfDNA release. There is much evidence to suggest that cfDNA is mainly derived from dying (i.e., apoptotic) cells. However, numerous cancer studies have shown that cfDNA is informative about acquired resistance to given therapies, which is present in living, proliferating tumor subclones. To explain this contradiction, we review current insights regarding cfDNA release, in particular the interplay between apoptosis and proliferation. We describe how improved knowledge about cfDNA biology could be used for novel therapeutic strategies and how this may affect patient management.Entities:
Keywords: apoptosis; biomarker; cell-free DNA; circulating tumor DNA; precision medicine; proliferation
Mesh:
Substances:
Year: 2020 PMID: 32359482 DOI: 10.1016/j.molmed.2020.01.012
Source DB: PubMed Journal: Trends Mol Med ISSN: 1471-4914 Impact factor: 11.951